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Highs and Lows in the
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La Jolla and San Diego, California
In recent years, we have come a long way from categorizing
all ankle-brachial indices (ABIs) above 0.90 as normal. Both
borderline low and high ABIs present significant risk (1). In
this issue of the Journal, Arain et al. (2) at the Mayo Clinic
document the risk of a high ABI with the largest such study
to date. The authors provide us with remarkable data,
presented clearly and concisely, on patients with “poorly
compressible arteries” (PCA). The more common term for
PCA is “high ABI,” since the ratio of the pressure at the
ankle to the arm is falsely elevated by selective stiffening of
the ankle, but not the brachial, arteries by medial arterial
calcinosis (MAC). Such falsely elevated ABI levels may
occur at ABI levels of 1.30, although 1.40, the cut point
used by the authors, is a more specific and conventional cut
point for high ABI. Such high ABIs are infrequent in
population studies, with prevalence estimates of 1.4% (3) to
2.8% (1). However, they are much more common in older
patients, and those with diabetes or chronic kidney disease
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(CKD), all groups at elevated risk of cardiovascular disease
(CVD) events. It is important to note that in MAC, the
calcification is in the arterial media, as opposed to the
intima, which is the typical location of atherosclerotic
calcification in the arteries (4). A number of population-
based cohort studies, carefully reviewed by Arain et al. (2),
have shown an increased risk of CVD events and total
mortality for those with high as well as low ABIs. Typically,
the risk in population studies for a high ABI is about the
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paper to disclose.same as for moderate peripheral artery disease (PAD), with
severe PAD showing a much higher risk (1).
Here, the authors studied a very large vascular lab cohort
of 16,493 patients, followed for a mean of almost 6 years,
with 54% having a low ABI and fully 17% having a high
ABI. Vascular lab patients have, of course, more extensive
disease than persons in population studies, so comparisons
of the risks of low versus high ABI may differ. After
adjustment for potential confounding factors including co-
morbid conditions, the authors report that relative to a
normal ABI, patients with a low ABI had a hazard ratio
(HR) of 1.6 for total mortality, patients with a high ABI
had a HR of 2.0, and the HR for high relative to a low ABI
was 1.3. Interestingly, and consistent with prior clinical
observations, there was more critical limb ischemia in the
high than in the low ABI patients (37% vs. 18.5%). After
adjustment for this marker of PAD severity, the HR for
high ABI relative to low ABI was reduced to 1.2, but
remained statistically significant.
This study highlights a number of important questions.
First, what is the probability of underlying PAD among
individuals with a high ABI? At least 3 prior studies have
evaluated this, with percentages of 56% (5), 62% (6), and
80% (7), although criteria for PAD differed somewhat in
these studies. Importantly, all 3 studies evaluated patients
referred to vascular labs, presumably primarily for leg
symptoms, and the underlying PAD prevalence in persons
with high ABI in the general population may be much less.
This latter question has not been studied.
Second, it is well documented that high ABIs are
associated with elevated CVD risk (1). Is this entirely due to
the presence of underlying PAD? In a study of 403
hospitalized patients with diabetes who had a vascular lab
exam, Aboyans and colleagues (5) categorized patients into
low and high ABI with the standard 0.90 and 1.40 cut
points, but in addition, recorded Doppler waveforms. This
allowed them to classify patients into 4 groups: no arterial
disease, PAD only, high ABI only, and PAD with high
ABI. Since all patients had diabetes, CVD and mortality
rates were high during follow-up. However, the CVD event
rate in those with high ABI only was similar to those with
neither PAD nor high ABI, and much lower than CVD
rates in those with PAD only or concomitant PAD and
high ABI. Thus, at least in this cohort of patients with
diabetes, high ABI alone did not influence outcome, nor did
it add to the hazard of occlusive PAD. The current Mayo
Clinic study also performed Doppler waveform analysis,
with abnormalities present in 71% of the patients with high
ABI. However, although high ABI patients with PAD had
a HR of 1.55 compared with high ABI patients without
PAD, the latter group still showed a HR of 1.4 compared
with patients with a normal ABI. Thus, the 2 studies differ
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Mayo Clinic study shows a striking excess of diabetes, heart
failure, and CKD in patients with high ABI, and indeed in
multivariate analysis, these conditions were the strongest
predictors of death. These conditions were dichotomized in
the multivariable analysis, and it seems possible that if
continuous or multicategorical definitions were used for
these comorbid conditions, greater attenuation of the effect
of high ABI without PAD might have been observed.
However, such detailed standardized data are not typically
available in clinical records in a large vascular population.
Although diabetes and CKD are likely true confounders,
heart failure is somewhat different. Heart failure was the
strongest single predictor of mortality in the current study,
and it is possible high ABI, as a marker of vascular stiffness,
could directly lead to heart failure through effects on the left
ventricle (8,9). If this hypothesis were true, high ABI could
directly influence mortality independent of an atheroscle-
rotic pathway by initiating or worsening heart failure. In this
situation, adjustment for heart failure when evaluating the
risk of a high ABI for mortality would be “overadjustment”
in the sense of adjusting for a variable in the causal pathway.
Next, what is the clinical significance of a high ABI in the
general population, and what are the risk factors? Existing
studies suggest that although age, diabetes, and CKD are
strongly associated with high ABI, most other atheroscle-
rotic risk factors are not. For example, smoking and hyper-
lipidemia do not show the associations seen for low ABI
(9–11). Other risk factors for a high ABI should be explored
(12), particularly those potentially amenable to modifica-
tion. If a high ABI leads to CVD and death through
pathways distinct from atherosclerosis, such studies might
ultimately provide new ways to retard progression to a high
ABI, which could translate into decreased CVD.
Finally, what is the clinician to do when presented with
an ABI 1.40? In current medical practice, the ABI is
primarily measured in the setting of leg discomfort, though
in fact, measurement for CVD risk prediction may be
reasonable (13). In the leg discomfort setting, the question
is whether there is underlying PAD. In this setting, if a high
ABI is detected, additional vascular testing should be
preformed. If PAD is present on additional testing, excel-
lent evidence supports aggressive risk factor modification to
reduce systemic CVD risk (14), as well as therapy to
improve physical functioning and quality of life, particularly
a supervised walking program (15). However, irrespective of
whether underlying PAD is present, high ABI appears to be
a marker for diabetes, CKD, heart failure, and early mor-tality. Thus, this finding should alert the clinician to the
need for additional investigation.
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